Table 3.
Incident Cancer Cases and Deaths in the BHCHP Cohort, With Age-Standardized Incidence and Mortality Ratios
| Male | Female | |||||||
|---|---|---|---|---|---|---|---|---|
| Cancer site/type | Incident cases | SIR (95% CI) | Deaths | SMR (95% CI) | Incident cases | SIR (95% CI) | Deaths | SMR (95% CI) |
| All sites | 361 | 1.13 (1.02–1.25) | 168 | 1.88 (1.61–2.19) | 98 | 0.93 (0.76–1.14) | 38 | 1.61 (1.14–2.20) |
| Brain and other nervous system | 5 | 0.94 (0.31–2.20) | 1–4 | 0.60 (0.07–2.15) | 0 | -- | 0 | -- |
| Breast | 0 | -- | 0 | -- | 21 | 0.59 (0.37–0.91) | 5 | 1.07 (0.35–2.50) |
| Bronchus and lung | 85 | 2.30 (1.84–2.84) | 61 | 2.39 (1.83–3.08) | 23 | 2.23 (1.41–3.35) | 14 | 2.31 (1.26–3.88) |
| Cervix uteri | N/A | -- | N/A | -- | 10 | 4.42 (2.12–8.12) | 1–4 | 6.01 (1.24–17.6) |
| Colon and rectum | 36 | 1.24 (0.87–1.71) | 19 | 2.37 (1.43–3.70) | 7 | 0.99 (0.40–2.03) | 1–4 | 1.61 (0.33–4.72) |
| Corpus uteri and uterus NOS | N/A | -- | N/A | -- | 1–4 | 0.54 (0.15–1.38) | 1–4 | 1.29 (0.03–7.17) |
| Esophagus | 10 | 1.51 (0.73–2.78) | 8 | 1.82 (0.79–3.59) | 0 | -- | 0 | -- |
| Hodgkin lymphoma | 1–4 | 0.37 (0.01–2.07) | 0 | -- | 0 | -- | 0 | -- |
| Kidney and renal pelvis | 10 | 0.69 (0.33–1.26) | 0 | -- | 1–4 | 0.43 (0.01–2.40) | 1–4 | 2.90 (0.07–16.2) |
| Larynx | 8 | 2.07 (0.90–4.09) | 1–4 | 3.13 (0.85–8.00) | 0 | -- | 0 | -- |
| Leukemia | 6 | 0.82 (0.30–1.79) | 1–4 | 1.28 (0.35–3.28) | 0 | -- | 0 | -- |
| Liver and intrahepatic bile ducts | 34 | 4.31 (2.99–6.02) | 22 | 4.35 (2.73–6.59) | 1–4 | 3.58 (0.43–12.9) | 0 | -- |
| Melanoma | 8 | 0.47 (0.20–0.92) | 1–4 | 1.77 (0.48–4.53) | 1–4 | 0.29 (0.03–1.04) | 0 | -- |
| Multiple myeloma | 1–4 | 1.08 (0.29–2.76) | 1–4 | 1.29 (0.16–4.67) | 1–4 | 1.47 (0.04–8.21) | 1–4 | 3.50 (0.09–19.5) |
| Non-Hodgkin lymphoma | 10 | 0.72 (0.35–1.33) | 1–4 | 0.33 (0.01–1.85) | 1–4 | 0.31 (0.01–1.73) | 0 | -- |
| Oral cavity and pharynx | 25 | 2.03 (1.31–3.00) | 9 | 2.37 (1.08–4.49) | 5 | 3.34 (1.08–7.79) | 1–4 | 2.81 (0.07–15.7) |
| Ovary | N/A | -- | N/A | -- | 1–4 | 0.63 (0.08–2.29) | 1–4 | 1.57 (0.19–5.66) |
| Pancreas | 11 | 1.64 (0.82–2.94) | 9 | 1.62 (0.74–3.07) | 1–4 | 1.24 (0.15–4.48) | 1–4 | 1.61 (0.20–5.83) |
| Prostate | 59 | 0.63 (0.48–0.81) | 1–4 | 0.92 (0.25–2.36) | N/A | -- | N/A | -- |
| Stomach | 8 | 1.60 (0.69–3.15) | 1–4 | 1.42 (0.39–3.63) | 1–4 | 2.75 (0.33–9.95) | 1–4 | 2.42 (0.06–13.5) |
| Testis | 0 | -- | 0 | -- | N/A | -- | N/A | -- |
| Thyroid | 1–4 | 0.29 (0.03–1.03) | 0 | -- | 5 | 0.52 (0.17–1.21) | 0 | -- |
| Urinary bladder | 17 | 0.93 (0.54–1.49) | 1–4 | 1.29 (0.35–3.30) | 1–4 | 0.53 (0.01–2.97) | 1–4 | 3.11 (0.08–17.3) |
Note: Cell sizes of 1–4 are suppressed for confidentiality.
BHCHP, Boston Health Care for the Homeless Program; SIR, standardized incidence ratio; SMR, standardized mortality ratio; NOS, not otherwise specified